Abstract
Purpose Non-specific vaginitis is a distinct clinical entity with particular microscopic and immunologic features. Currently, there is no standard of care for women with non-specific vaginitis. The aim of our study was to assess the change in vaginal symptoms score after a 3-months treatment with Cerviron® medical device in participants with abnormal vaginal discharge and with specific signs and symptoms. As secondary objectives, the study analyzed other clinical and microscopic features, such as vaginal discharge aspect, change in vaginal pH, change in vaginal microbiome, and vaginal inflammation.
Methods The study population included 47 participants suffering from symptomatic vulvovaginitis, distinct from candidiasis, trichomoniasis or bacterial vaginosis. The study design included 2 research sites from Romania. The treatment protocol consisted of 1 ovule/day inserted intravaginally, during 15 consecutive days. The total study duration was 3 months.
Findings Cerviron® had a positive impact on the vaginal symptoms score for 72.34% of the study participants. Topical administration of Cerviron® balanced vaginal pH values and significantly reduced signs of inflammation between study visits.
Implications Cerviron® shows curative effects that supports its use as a stand-alone treatment in women with non-specific vaginitis. ClinicalTrials.gov identifier: NCT04735705.
A second clinical investigation is ongoing to evaluate its clinical efficacy in postoperative care of cervical and vaginal wounds, traumatic or secondary to surgical interventions.
Competing Interest Statement
MDX Research was involved in the study design, site selection, collection, statistical analysis and preparation of the manuscript. The authors have indicated that they have no other conflicts of interest regarding the content of the present article.
Clinical Trial
NCT04735705
Funding Statement
Perfect Care Distribution provided financial support for the clinical investigation. However, Perfect Care Distribution had no involvement in the study design, the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the article for publication
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The National Medical Devices and Medicines Bioethics Committee (CNBMDM) approved the present clinical investigation with number 1DM from 01 April 2021 (protocol number CYRON/01/2021; NCT04735705).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.